Analyst Ranking
Top 46%
#2310 out of 5071 analysts
Average Return
+0.17%
Win Rate
40%33 out of 82
Risk vs Reward
Poor
Good

Evan Seigerman's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Disc Medicine IncIRON
+165.37%$22.84$60.61
2023-03-22 -
2024-03-22
Buy
Disc Medicine IncIRON
+84.87%$46.61$86.17
2025-05-11 -
2025-10-21
Buy
Eli Lilly & CoLLY
+71.55%$428.44$734.97
2023-05-03 -
2024-05-03
Buy
Structure Therapeutics IncGPCR
+69.29%$25.56$43.27
2023-02-27 -
2024-02-28
Buy
Gilead Sciences IncGILD
+62.11%$73.66$119.41
2024-08-08 -
2025-08-08
Buy

Evan Seigerman's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Vertex Pharmaceuticals IncVRTX
14Buy$530.00+24.33%Maintains
3 months ago
Incyte CorpINCY
9Sell$60.00-31.27%Maintains
3 months ago
Disc Medicine IncIRON
5Buy$120.00+39.26%Maintains
5 months ago
Neurocrine Biosciences IncNBIX
11Hold$115.00-19.38%Maintains
6 months ago
Gilead Sciences IncGILD
14Buy$120.00-3.29%Maintains
6 months ago
Biogen IncBIIB
15Hold$139.00-4.94%Maintains
8 months ago
Bristol Myers Squibb CoBMY
11Hold$61.00+36.96%Maintains
a year ago
Eli Lilly & CoLLY
8Buy$1,101.00N/AMaintains
a year ago
Structure Therapeutics IncGPCR
1Buy$40.00N/AInitiates Coverage On
3 years ago
Mirati Therapeutics IncMRTX
4Hold$59.00N/ADowngrades
3 years ago
Replimune Group IncREPL
1Buy$40.00N/AMaintains
3 years ago
Regeneron Pharmaceuticals IncREGN
9Buy$788.00N/AMaintains
3 years ago
Nuvation Bio IncNUVB
2Hold$2.50N/ADowngrades
3 years ago
Candel Therapeutics IncCADL
2Buy$12.00N/AMaintains
4 years ago
Pfizer IncPFE
1Buy$60.00N/AInitiates Coverage On
4 years ago
Amgen IncAMGN
4Hold$228.00N/AInitiates Coverage On
4 years ago
Imagenebio IncIMA
2Buy$324.00N/AMaintains
4 years ago
Satsuma Pharmaceuticals IncSTSA
2Hold$6.50N/AUpgrades
5 years ago
Galera Therapeutics IncGRTX
2Buy$15.00N/AUpgrades
5 years ago
Aimmune Therapeutics IncAIMT
3Hold$34.50N/AMaintains
5 years ago
Talphera IncTLPH
5Sell$16.80N/AMaintains
5 years ago
Macrogenics IncMGNX
1Buy$13.00N/AMaintains
5 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.